These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37951787)

  • 1. Palliative care needs among outpatient adults with cystic fibrosis: Baseline data from the Improving Life with CF trial.
    DiFiglia S; Georgiopoulos AM; Portenoy R; Seng E; Berdella M; Friedman D; Kier C; Linnemann RW; Middour-Oxler B; Walker P; Wang J; Yonker LM; Buehler B; Chaudhary N; Esposito C; Frantzen T; Henthorne K; Plachta A; Pollinger S; Stables-Carney T; Trentacoste J; Dhingra L
    J Cyst Fibros; 2024 Jul; 23(4):804-810. PubMed ID: 37951787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis.
    Georgiopoulos AM; DiFiglia S; Seng EK; Portenoy R; Chaudhary N; Wei R; Berdella MN; Friedman D; Kier C; Linnemann RW; Middour-Oxler B; Stables-Carney T; Walker P; Wang J; Yonker LM; Dhingra L
    Pediatr Pulmonol; 2024 Nov; 59(11):2857-2866. PubMed ID: 38934771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of unmet palliative care needs in adults with cystic fibrosis.
    Trandel ET; Pilewski JM; Dellon EP; Jeong K; Yabes JG; Moreines LT; Arnold RM; Hoydich ZP; Kavalieratos D
    J Cyst Fibros; 2020 May; 19(3):394-401. PubMed ID: 31862306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden.
    Lindblad A; Monestrol I; Gilljam M; Krantz C; McGarry LJ; Banefelt J; Aldvén M
    J Med Econ; 2024; 27(1):897-906. PubMed ID: 38939921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
    Calthorpe RJ; Goodchild N; Gleetus V; Premakumar V; Hayee B; Elliott Z; Evans B; Rowbotham NJ; Carr SB; Barr H; Horsley A; Peckham D; Smyth AR
    NIHR Open Res; 2023; 3():18. PubMed ID: 37881465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring Opportunities for Primary Outpatient Palliative Care for Adults with Cystic Fibrosis: A Mixed-Methods Study of Patients' Needs.
    Hobler MR; Engelberg RA; Curtis JR; Ramos KJ; Zander MI; Howard SS; Goss CH; Aitken ML
    J Palliat Med; 2018 Apr; 21(4):513-521. PubMed ID: 29298400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms and quality of life in adults with cystic fibrosis: A cross-sectional analysis of the InSPIRe:CF trial.
    Smirnova N; Lowers J; Cammarata-Mouchtouris A; Dellon EP; Fitzpatrick A; Kavalieratos D
    J Cyst Fibros; 2024 Sep; 23(5):831-835. PubMed ID: 38461123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the burden of illness in adults with cystic fibrosis with screening and triage: An early intervention model of palliative care.
    Dhingra L; Walker P; Berdella M; Plachta A; Chen J; Fresenius A; Balzano J; Barrett M; Bookbinder M; Wilder K; Glajchen M; Langfelder-Schwind E; Portenoy RK
    J Cyst Fibros; 2020 Mar; 19(2):262-270. PubMed ID: 31471264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
    Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
    Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
    Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
    Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom Burden and Unmet Existential Needs in Adults With Cystic Fibrosis.
    Trandel ET; Pilewski JM; Dellon EP; Moreines LT; Yabes JG; Jeong K; Arnold RM; Kavalieratos D
    West J Nurs Res; 2019 Oct; 41(10):1448-1464. PubMed ID: 31267835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping.
    Friedman D; Linnemann RW; Altstein LL; Islam S; Bach KT; Lamb C; Volpe J; Doolittle C; St John A; O'Malley PJ; Sawicki GS; Georgiopoulos AM; Yonker LM; Moskowitz SM
    J Cyst Fibros; 2018 Jan; 17(1):71-77. PubMed ID: 28302366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.
    Sawicki GS; Van Brunt K; Booth J; Bailey E; Millar SJ; Konstan MW; Flume PA
    J Cyst Fibros; 2022 Jan; 21(1):96-103. PubMed ID: 34289939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis.
    Talwalkar JS; Koff JL; Lee HB; Britto CJ; Mulenos AM; Georgiopoulos AM
    Psychosomatics; 2017; 58(4):343-354. PubMed ID: 28576305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis.
    Friedman D; Linnemann RW; Altstein LL; Georgiopoulos AM; Islam S; Bach KT; St John A; Fracchia MS; Neuringer I; Lapey A; Sicilian L; Moskowitz SM; Yonker LM
    Pediatr Pulmonol; 2019 Jul; 54(7):984-992. PubMed ID: 30854795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy.
    Gifford AH; Mayer-Hamblett N; Pearson K; Nichols DP
    J Cyst Fibros; 2020 Sep; 19(5):762-767. PubMed ID: 31761739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.